Anti-islet cell and anti-insulin antibody production by CD5+ and CD5- B lymphocytes in IDDM

A. Muñoz, T. Gallart, E. F. Usac, J. Fernández-Alvarez, O. Viñas, N. Somoza, J. Barceló, R. Gomis

    Research output: Contribution to journalArticleResearchpeer-review

    12 Citations (Scopus)


    Although CD5+B lymphocytes are mostly committed to the production of polyreactive natural autoantibodies, CD5+B lymphocytes committed to the production of somatically mutated and monoreactive high-affinity IgM autoantibodies have been also shown. Increased proportions of CD5+B lymphocytes in some autoimmune diseases, including insulin-dependent diabetes mellitus (IDDM), have been noticed. The present study was undertaken to analyse the differences between CD5+ and CD5-B lymphocyte subsets for production of IDDM-related autoantibodies, i.e. anti-human insulin antibodies (IA) and anti-human islet cell antibodies (ICA). For this purpose, Epstein-Barr Virus (EBV)-transformation of FACS cell-sorted CD5+ and CD5-B lymphocytes and unfractionated enriched B lymphocytes from nine IDDM patients treated exclusively with recombinant human insulin, and from four healthy control subjects was performed; a mean of 102–216 microcultures with a mean of 1,000–2,333 cells/microculture for each B-lymphocyte fraction and individual was established. Data show that both CD5+ and CD5-B-lymphocyte subsets from either normal subjects or from IDDM patients receiving recombinant human insulin, contain B lymphocytes committed to the production of IA-IgM as a common element of their repertoire. In contrast, cells committed to the production of IA-IgG were only detected among the CD5-B lymphocyte subset from some IDDM patients. Only one microculture, out of a total of 6,211 screened (from control subjects and patients), in the CD5-B-cell subset from a recently-diagnosed IDDM patient, was found to produce ICA-IgMλ. This might suggest that the frequency of circulating B lymphocytes committed to the production of ICA is very low even in IDDM patients bearing serum ICA. EBV-transformed B cells producing the ICA-IgMψ were stabilized and cloned by somatic hybridization technique. This ICA-IgMψ human monoclonal antibody, designated HY1-MB91, is not polyreactive, but shows a restricted reactivity with human pancreatic islets, failing to react with other human tissues including cerebellar cortex, and lacking rheumatoid factor and anti-DNA antibody activities. It also lacks reactivity with pancreatic islets from other mammalian species (rat, mouse and monkey) as well as with other rat tissues, including cerebellar cortex. The antigen recognized by HY1-MB91 antibody in human islet cells is a cytoplasmic component mostly found in beta cells. [Diabetologia (1995) 38:62–72] © 1995, Springer-Verlag. All rights reserved.
    Original languageEnglish
    Pages (from-to)62-72
    JournalDiabetologia: Clinical and Experimental Diabetes and Metabolism
    Publication statusPublished - 1 Jan 1995


    • CD5+B lymphocytes
    • EBV-transformed B cells
    • anti-insulin antibodies
    • anti-islet cell antibodies
    • human monoclonal antibody


    Dive into the research topics of 'Anti-islet cell and anti-insulin antibody production by CD5+ and CD5- B lymphocytes in IDDM'. Together they form a unique fingerprint.

    Cite this